Abstract
Cancer is a highly heterogeneous disease at intra/inter patient levels and known as the leading cause of death worldwide. A variety of mono and combinational therapies including chemotherapy have been evolved over the years for its effective treatment. However, advent of chemotherapeutic resistance or multidrug resistance (MDR) in cancer is a major challenge researchers are facing in cancer chemotherapy. MDR is a complex process having multifaceted non-cellular or cellular-based mechanisms. Research in the area of cancer nanotechnology over the past two decade has now proven that the smartly designed nanoparticles help in successful chemotherapy by overcoming the MDR and preferentially accumulate in the tumor region by means of active and passive targeting therefore reducing the offtarget accumulation of payload. Many of such nanoparticles are in different stages of clinical trials as nanomedicines showing promising result in cancer therapy including the resistant cases. Nanoparticles as chemotherapeutics carriers offer the opportunity to have multiple payload of drug and or imaging agents for combinational and theranostics therapy. Moreover, nanotechnology further bring in notice the new treatment strategies such as combining the NIR, MRI and HIFU in cancer chemotherapy and imaging. Here, we discussed the cellular/non-cellular factors constituting the MDR in cancer and the role of nanomedicines in effective chemotherapy of MDR cases of cancers. Moreover, recent advancements like combinational payload delivery and combined physical approach with nanotechnology in cancer therapy have also been discussed.
Keywords: Multidrug resistance, MDR, efflux transporter, nanoparticles, passive targeting, active targeting, pH-sensitive, HIFU, combinational drug targeting.
Current Pharmaceutical Design
Title:Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Volume: 22 Issue: 28
Author(s): Javed Ahmad, Sohail Akhter, Mohammad Ahmed Khan, Muhammad Wahajuddin, Nigel H. Greig, Mohammad Amjad Kamal, Patrick Midoux and Chantal Pichon
Affiliation:
Keywords: Multidrug resistance, MDR, efflux transporter, nanoparticles, passive targeting, active targeting, pH-sensitive, HIFU, combinational drug targeting.
Abstract: Cancer is a highly heterogeneous disease at intra/inter patient levels and known as the leading cause of death worldwide. A variety of mono and combinational therapies including chemotherapy have been evolved over the years for its effective treatment. However, advent of chemotherapeutic resistance or multidrug resistance (MDR) in cancer is a major challenge researchers are facing in cancer chemotherapy. MDR is a complex process having multifaceted non-cellular or cellular-based mechanisms. Research in the area of cancer nanotechnology over the past two decade has now proven that the smartly designed nanoparticles help in successful chemotherapy by overcoming the MDR and preferentially accumulate in the tumor region by means of active and passive targeting therefore reducing the offtarget accumulation of payload. Many of such nanoparticles are in different stages of clinical trials as nanomedicines showing promising result in cancer therapy including the resistant cases. Nanoparticles as chemotherapeutics carriers offer the opportunity to have multiple payload of drug and or imaging agents for combinational and theranostics therapy. Moreover, nanotechnology further bring in notice the new treatment strategies such as combining the NIR, MRI and HIFU in cancer chemotherapy and imaging. Here, we discussed the cellular/non-cellular factors constituting the MDR in cancer and the role of nanomedicines in effective chemotherapy of MDR cases of cancers. Moreover, recent advancements like combinational payload delivery and combined physical approach with nanotechnology in cancer therapy have also been discussed.
Export Options
About this article
Cite this article as:
Ahmad Javed, Akhter Sohail, Khan Ahmed Mohammad, Wahajuddin Muhammad, Greig H. Nigel, Kamal Amjad Mohammad, Midoux Patrick and Pichon Chantal, Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective, Current Pharmaceutical Design 2016; 22 (28) . https://dx.doi.org/10.2174/1381612822666160617112111
DOI https://dx.doi.org/10.2174/1381612822666160617112111 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Post-traumatic Stress Disorder in Heart Failure Patients: A Test of the Cardiac Disease-induced PTSD Hypothesis
Current Psychiatry Research and Reviews TSH Variations in Chronic Heart Failure Outpatients: Clinical Correlates and Outcomes
Endocrine, Metabolic & Immune Disorders - Drug Targets The Impact of Opioids on Cardiac Electrophysiology
Current Cardiology Reviews Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents
Current Pharmaceutical Biotechnology Why Multiples of 21? Why does Selenoprotein P Contain Multiple Selenocysteine Residues?
Current Nutraceuticals Endothelin Signalling in the Cardiac Myocyte and its Pathophysiological Relevance
Current Vascular Pharmacology Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Role of PI3 Kinase Gamma in Excitation-Contraction Coupling and Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets Pathophysiological Roles of Nitric Oxide: In the Heart and the Coronary Vasculature
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Electrocardiographic Abnormalities in Thalassemia Patients with Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Antiviral Drug Discovery Targeting to Viral Proteases
Current Pharmaceutical Design Human Heart Failure: A Proteomics Perspective
Current Proteomics Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients
Current Cancer Therapy Reviews The Cardiac Conduction and Contractility Complications of Methamphetamine Use and the Relationship to Psychiatric Comorbidity: A Systematic Review
Current Psychiatry Research and Reviews Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology